Literature DB >> 9428622

Evidence for a role of oxygen-derived free radicals and protein kinase C in nitrate tolerance.

T Münzel1, D G Harrison.   

Abstract

The anti-ischemic effects of organic nitrates are rapidly attenuated due to the development of nitrate tolerance. The mechanisms underlying this phenomenon likely involve several independent factors. As a vasodilator, nitroglycerin activates compensatory neurohumoral mechanisms such as the renin-angiotensin system and increases catecholamine and vasopressin levels, all of which may attenuate its vasodilator potency. Tolerance may be also due to the inability of the vessel to dilate after prolonged treatment with the nitrate. More recent experimental studies have challenged traditional tolerance concepts by demonstrating that tolerance is not associated with sulfhydryl group depletion, reduced nitroglycerin biotransformation, or desensitization of the target enzyme guanylyl-cyclase. Experimental and clinical observations suggest that tolerance may be the consequence of intrinsic abnormalities of the vasculature, including enhanced endothelial production of oxygen-derived free radicals secondary to an activation of NAD(P)H-dependent oxidases and an activation of PKC. Superoxide degrades nitric oxide derived from nitroglycerin (NTG) while C activation causes enhanced sensitivity of the vasculature to circulating neurohormones such as catecholamines, angiotensin II, and serotonin, all of which may compromise the vasodilator potency of NTG. Interestingly, these vascular consequences of in vivo NTG treatment such as superoxide production and PKC activation can be mimicked in vitro by incubating cultured endothelial and smooth muscle cells with angiotensin II. Furthermore, nitrate tolerance and rebound following sudden cessation of prolonged NTG therapy can be prevented by concomitant treatment with high-dose angiotensin-converting enzyme inhibition, angiotensin type 1 receptor blockade, or antioxidants such as hydralazine. Thus one can conclude that neurohumoral counterregulatory mechanisms such as increased circulating levels of angiotensin II may be at least in part responsible for tolerance mechanisms at the cellular level.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9428622     DOI: 10.1007/s001090050181

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  11 in total

1.  The nitric oxide donor SIN-1 is free of tolerance and maintains its cyclic GMP stimulatory potency in nitrate-tolerant LLC-PK1 cells.

Authors:  B Hinz; H Schröder
Journal:  Pharm Res       Date:  1999-05       Impact factor: 4.200

Review 2.  Crosstalk between endothelin and nitric oxide in the control of vascular tone.

Authors:  M Lavallée; M Takamura; R Parent; E Thorin
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

3.  The nitric oxide donor pentaerythritol tetranitrate can preserve endothelial function in established atherosclerosis.

Authors:  A Hacker; S Müller; W Meyer; G Kojda
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

4.  Effects of telmisartan or amlodipine monotherapy versus telmisartan/amlodipine combination therapy on vascular dysfunction and oxidative stress in diabetic rats.

Authors:  Hanke Mollnau; Matthias Oelze; Elena Zinßius; Michael Hausding; Zhixiong Wu; Maike Knorr; Jasmin Ghaemi Kerahrodi; Swenja Kröller-Schön; Thomas Jansen; Christine Teutsch; Carolyn Foster; Huige Li; Philip Wenzel; Eberhard Schulz; Thomas Münzel; Andreas Daiber
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-02-27       Impact factor: 3.000

5.  Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis.

Authors:  Volker O Melichar; Delphine Behr-Roussel; Ulrike Zabel; L Otto Uttenthal; José Rodrigo; Alain Rupin; Tony J Verbeuren; Arun Kumar H S; Harald H H W Schmidt
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-16       Impact factor: 11.205

6.  Nicorandil as a novel therapy for advanced diabetic nephropathy in the eNOS-deficient mouse.

Authors:  Katsuyuki Tanabe; Miguel A Lanaspa; Wataru Kitagawa; Christopher J Rivard; Makoto Miyazaki; Jelena Klawitter; George F Schreiner; Moin A Saleem; Peter W Mathieson; Hirofumi Makino; Richard J Johnson; Takahiko Nakagawa
Journal:  Am J Physiol Renal Physiol       Date:  2012-02-15

7.  Nitric oxide modulators: an emerging class of medicinal agents.

Authors:  S R Deshpande; K Satyanarayana; M N A Rao; K V Pai
Journal:  Indian J Pharm Sci       Date:  2012-11       Impact factor: 0.975

Review 8.  Organic nitrates and nitrate resistance in diabetes: the role of vascular dysfunction and oxidative stress with emphasis on antioxidant properties of pentaerithrityl tetranitrate.

Authors:  Matthias Oelze; Swenja Schuhmacher; Andreas Daiber
Journal:  Exp Diabetes Res       Date:  2010-12-27

9.  Heme oxygenase-1 induction and organic nitrate therapy: beneficial effects on endothelial dysfunction, nitrate tolerance, and vascular oxidative stress.

Authors:  Andreas Daiber; Matthias Oelze; Philip Wenzel; Franziska Bollmann; Andrea Pautz; Hartmut Kleinert
Journal:  Int J Hypertens       Date:  2012-03-07       Impact factor: 2.420

10.  Detection of reactive oxygen species in isolated, perfused lungs by electron spin resonance spectroscopy.

Authors:  Norbert Weissmann; Nermin Kuzkaya; Beate Fuchs; Vedat Tiyerili; Rolf U Schäfer; Hartwig Schütte; Hossein A Ghofrani; Ralph T Schermuly; Christian Schudt; Akylbek Sydykov; Bakytbek Egemnazarow; Werner Seeger; Friedrich Grimminger
Journal:  Respir Res       Date:  2005-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.